Dr David Paul Parker, MD | |
16251 Sylvester Rd Sw, Burien, WA 98166-3017 | |
(206) 214-6530 | |
Not Available |
Full Name | Dr David Paul Parker |
---|---|
Gender | Male |
Speciality | Emergency Medicine |
Location | 16251 Sylvester Rd Sw, Burien, Washington |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1295896488 | NPI | - | NPPES |
8355042 | Medicaid | WA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | MD00041676 (Washington) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr David Paul Parker, MD 16251 Sylvester Rd Sw, Burien, WA 98166-3017 Ph: (206) 214-6530 | Dr David Paul Parker, MD 16251 Sylvester Rd Sw, Burien, WA 98166-3017 Ph: (206) 214-6530 |
News Archive
Pfizer Inc. and Ligand Pharmaceuticals Incorporated today announced that the United States Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for non-hysterectomized women for the treatment of moderate-to-severe vasomotor symptoms (VMS) and vulvar and vaginal atrophy (VVA) associated with menopause, as well as the prevention of postmenopausal osteoporosis.
With the rate of chronic kidney disease on the rise among older Americans, researchers seeking to improve patients' quality of life studied a group of adults undergoing hemodialysis and found their higher rates of depression and anxiety could be associated with their impaired physical exercise capability and reduced daily physical activity, according a new study published online by the Journal of Renal Nutrition.
Better community education and communication are critical for increasing levels of blood donation among minorities, according to a study by researchers at Georgia State University and Georgia Southern University.
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the design of its planned Phase III registration clinical trial of Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega 3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
› Verified 2 days ago
Dr. Gregory Paul Garcia, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 16251 Sylvester Rd Sw, Burien, WA 98166 Phone: 206-431-5316 | |
Dr. Thomas Michael Ryan, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 16251 Sylvester Rd Sw, Burien, WA 98166 Phone: 206-431-5316 | |
Dr. Alan Ehrlich, Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 16255 Sylvester Rd Sw, Burien, WA 98166 Phone: 206-431-5316 | |
Tonia Willekes, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 16251 Sylvester Rd Sw, Burien, WA 98166 Phone: 206-431-5316 | |
Gilbert S Chen, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 16251 Sylvester Rd Sw, Burien, WA 98166 Phone: 206-244-9970 | |
Glenn Alan Zerby, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2724 Sw 167th St, Burien, WA 98166 Phone: 206-439-7992 |